Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07012148 · ClinicalTrials.gov registry record · NA

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

A NA study of Focal Epilepsy and Generalized Seizure, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT07012148 is a NA study of Focal Epilepsy and Generalized Seizure that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 12 participants, below the 171-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07012148, a NA study of Focal Epilepsy and Generalized Seizure, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and feasibility of using seizure forecasts based on subscalp EEG.

Interventions

  • DEVICE UNEEG SubQ device

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2026-01-20
Est. Completion 2029-12
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT07012148

The ClinicalTrials.gov registry entry for NCT07012148 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (93% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Focal Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which UNEEG SubQ device is the first listed.

NCT07012148 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT07012148 about?

NCT07012148 is a clinical study titled "Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables". The purpose of this study is to evaluate the safety and feasibility of using seizure forecasts based on subscalp EEG.

What is the current status of trial NCT07012148?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2026-01-20. Estimated completion is 2029-12.

What conditions does trial NCT07012148 study?

This clinical trial studies the following conditions: Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy.

What interventions are being tested in trial NCT07012148?

The interventions under investigation include: UNEEG SubQ device (DEVICE).

Who is sponsoring clinical trial NCT07012148?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07012148 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Focal Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.